Dissertation (Ph.D.) -- University of Texas Southwestern Medical Center at Dallas, 2006. / Vita. Bibliography: p. 87-94.

Endosomes are now recognized as important sites for regulating signal transduction. Here we show that the lipid kinase phosphatidylinositol 4-kinase III beta (PI4KIIIβ) regulates both endocytic kinetics and receptor signaling in breast cancer cells. PI4KIIIβ generates phosphatidylinositol 4-phosphate from phosphatidylinositol and is highly expressed in a subset of breast cancers. However, the molecular mechanism by which PI4KIIIβ promotes breast cancer is unclear. We demonstrate that ectopic PI4KIIIβ expression increases the rates of both endocytic internalization and recycling. Furthermore, PI4KIIIβ deletion reduces endocytic kinetics. Regulation of endocytic function by PI4KIIIβ is independent of its kinase activity but requires interaction with the Rab11a GTPase. Additionally, we find that PI4KIIIβ activates IGF-IRβ signaling, dependent on endosome function. Finally, we observe that PI4KIIIβ deletion decreases the growth rate of mammary tumours in mice. Our work suggests a novel regulatory role for PI4KIIIβ in endosome function and plasma membrane receptor signaling, providing a mechanism by which increased PI4KIIIβ expression could promote breast cancer oncogenesis.

京都大学 / 0048 / 新制・課程博士 / 博士(人間健康科学) / 甲第20293号 / 人健博第41号 / 新制||人健||4(附属図書館) / 京都大学大学院医学研究科人間健康科学系専攻 / (主査)教授 高桑 徹也, 教授 岩井 一宏, 教授 精山 明敏 / 学位規則第4条第1項該当 / Doctor of Human Health Sciences / Kyoto University / DFAM

In Saccharomyces cerevisiae, experiments with temperature-sensitive mutants of the PI4-kinase Pik1p revealed that the PI4P pool generated by this enzyme is essential for Golgi morphology and normal secretory function and that the PI4P pool at the Golgi represents a regulatory signal on its own. In order to function as a spatial and temporal regulator of membrane traffic, PI4P synthesis and turnover must be tightly regulated. It remains elusive which factors are involved in the targeting and regulation of Pik1p. Little is also known about PI4P binding proteins mediating the effects of this phosphoinositide on Golgi function. Since it has been shown that multiple pathways leave the Golgi towards the plasma membrane one can ask the question whether Pik1p and its product PI4P specifically control one pathway? Here we demonstrate an interaction of Pik1p with the 14-3-3 proteins Bmh1p and Bmh2p. Interestingly, overexpression of Bmh1p and Bmh2p results in multiple genetic interactions with genes involved in late steps of exocytosis and it affects the forward transport of the general amino acid permease Gap1p. The detected interaction depends on the phosphorylation state of Pik1p and Pik1p phosphorylation accompanies its shuttling out of the nucleus into the cytoplasm where presumably the binding to Bmh1/2p occurs. Therefore, we reason that these interactions might serve the sequestration of Pik1p away from the Golgi. This study reveals that Pik1p shows a strong effect on the delivery of Gap1p to the surface whereas the transport of exocytosis markers implicated in the direct Golgi-to-plasma membrane pathway are not significantly disturbed. Cells carrying a deletion of gga2 also show a strong defect in delivery of Gap1p to the surface. In addition, pik1-101 gga2[delta]double mutants display synthetic genetic and membrane transport phenotypes and recruitment of Gga2 to the TGN partially depends on functional Pik1p. Therefore, our results suggest a role of Pik1p in the TGN to endosome pathway.

Une distribution lipidique hétérogène est essentielle à l’identité et fonction des organelles, mais l’échange par trafic vésiculaire tend à annuler cette distribution. Il existe donc des mécanismes qui assurent l’homéostasie des lipides. Les protéines Osh (S. cerevisiae) et les OSBP-Related Proteins (ORP, H. sapiens), sont des transporteurs de lipides. Osh4 est capable d’échanger de l’ergostérol contre le phosphatidylinositol-4-phosphate (PI4P), présent sur l’appareil de Golgi. Utilisant des outils fluorescents mesurant avec une précision inégalée le transport de stérol et de PI4P, nous démontrons qu’Osh4 transporte du stérol contre son gradient de concentration en utilisant l’énergie d’un gradient de PI4P. Un couplage au métabolisme du PI4P permettrait à Osh4 d’alimenter le Golgi avec du stérol, ainsi créant le gradient de stérol entre ces organelles. La protéine OSBP participe, via sa capacité à connecter la membrane du RE à celle du trans-Golgi, à la création de jonctions entre ces organelles. Nous avons montré qu’OSBP, par échange stérol/PI4P, utilise le PI4P pour transférer du cholestérol au Golgi, mais également pour autoréguler sa capacité à former les jonctions. Osh6 lie la phosphatidylsérine, nous permettant d’étudier un nouveau mécanisme d’échange. Nous avons résolu la structure cristallographique d’un complexe Osh6/PI4P et avons pu observer l’échange de ces deux ligands par Osh6 entre deux membranes. Cette étude nous permet de suggérer que l’échange de PI4P avec divers lipides, via les protéines Osh/ORP, serait un mécanisme général permettant aux cellules de maintenir le gradient lipidique entre le RE et les membranes tardives de la voie sécrétoire. / An uneven lipid distribution is essential for the function of eukaryotic organelles. However, exchange of material by vesicular trafficking has a tendency to perturb this distribution; mechanisms must though exist to ensure lipid homeostasis. Osh proteins (S. cerevisiae) and OSBP-Related Proteins (ORPs, H. sapiens), are lipid transfer proteins (LTPs). Osh4 is capable of exchanging ergosterol for phosphatidylinositol 4-phosphate (PI4P), found on the Golgi. Using novel fluorescent tools to measure with unprecedented precision the transport of sterol and PI4P, we find that Osh4 can transport sterol against its concentration gradient using the energy of a PI4P gradient. Coupled to phosphoinositide metabolism, this allows Osh4 to transport sterol to the trans-Golgi and create the sterol gradients observed between these organelles. OSBP participates in the creation of membrane contact sites (MCSs) via its capacity to connect ER membranes to those of the trans-Golgi. We have shown that it uses PI4P for transporting cholesterol from the ER to the trans-Golgi by sterol/PI4P counterexchange, hence also autoregulating its tethering activity. Finally, the identification of phosphatidylserine as a ligand for Osh6 allowed us to analyze the possible extrapolation of the PI4P counterexchange mechanism. We have solved the crystal structure of Osh6 in complex with PI4P and have been able to follow counterexchange of PI(4)P and PS in vitro. Concluding, our studies allow us to suggest a general mechanism for ORP/Osh-mediated counterexchange of PI4P for other lipids to maintain lipid gradients between the ER and late membranes of the secretory pathway.

Le virus de l’hépatite C (VHC) est l’un des principaux facteurs étiologiques du carcinome hépatocellulaire. Le traitement des hépatites virales C a été récemment amélioré grâce à une trithérapie (interféron, ribavirine et anti-protéase virale). Néanmoins l’importance des effets secondaires et l’émergence de mutants résistants nécessitent de découvrir de nouveaux antiviraux. Dans ce contexte, notre équipe a récemment découvert que les phosphatidylinositol 4-kinases de type III (PI4KIIIα et PI4KIIIβ) étaient indispensables à la propagation du virus dans une lignée hépatique humaine, et ce, à 2 étapes de son cycle biologique : l’entrée et la réplication. L’objectif du présent travail était de poursuivre la validation de ces nouvelles cibles thérapeutiques potentielles, en approfondissant nos connaissances sur la dépendance du virus à l’égard de ces kinases au cours de son entrée. Pour cela, nous avons utilisé le modèle des hépatocytes humains primaires, système in vitro plus proche du contexte physiologique que les modèles utilisés jusqu’à présent et qui étaient basés sur l’exploitation de lignées. Deux axes ont été développés : Vérification de l’importance de l’activité kinase des PI4KIIIs au cours de l’entrée du VHC dans les hépatocytes humains primaires, à travers une approche chimique ; Validation de l’implication de ces kinases et de leur activité enzymatique au cours de l’entrée virale grâce à une approche génétique basée sur l’ARN interférence et la restauration de phénotype. En parallèle, nous avons étudié l’expression de PI4KIIIα au cours de pathologies hépatiques. Nos résultats suggèrent une implication de PI4KIIIα au cours de l’entrée du VHC dans les hépatocytes humains primaires, mais restent à confirmer quant à l’implication de PI4KIIIβ. Par ailleurs, l’analyse de l’expression de PI4KIIIα dans le carcinome hépatocellulaire (CHC) conduit à proposer cette kinase comme un nouveau marqueur moléculaire, qui pourrait améliorer les modèles de pronostic déjà établis et pourrait conduire au développement de nouvelles approches thérapeutiques pour les patients atteints d’un CHC, quelque soit l’étiologie. / Hepatitis C virus (HCV) is one of the leading causes of hepatocellular carcinoma. Therapeutic treatment against the virus has been recently improved by a tritherapy including pegylated interferon, ribavirin and antiviral protease. Nevertheless, the importance of side effects and the emergence of resistant mutants require the development of new antivirals. In this context, our team has recently discovered that Type III phosphatidylinositol 4-kinases (PI4KIIIα and PI4KIIIβ) are essential for the propagation of the virus in a human hepatic cell line at the entry and replication steps. To further characterize these potential therapeutic targets, we investigate the implication of these kinases during the HCV entry, using primary human hepatocytes, a model closer to the in vivo conditions. Two lines of research were developed: Verification of the importance of the kinase activity of PI4KIIIs during HCV entry in primary human hepatocytes, through a chemical approach; Validation of the involvement of these kinases and their enzymatic activity during viral entry through a genetic approach based on RNA interference and phenotype rescue. In parallel, we studied the expression of PI4KIIIα in liver diseases. Our results suggest the involvement of PI4KIIIα in HCV entry; the involvement of PI4KIIIIβ needs to be confirmed. The analysis of PI4KIIIα expression in hepatocellular carcinoma led us to propose this kinase as a new molecular marker, which could improve the already established prognosis models and could lead to the development of new therapeutic approaches.

As doenças alérgicas alcançaram proporções mundialmente epidêmicas. A ativação de receptores para IgE, Fc RI, em mastócitos, é o mecanismo chave para a iniciação e propagação das respostas patofisiológicas dos processos alérgicos. Após a interação destas células com um alérgeno, há a ativação de uma cascata de eventos de sinalização, a qual resulta na secreção de mediadores alérgicos pré-formados, através de um processo regulado de exocitose, além da síntese e secreção de mediadores lipídicos e citocinas. Desta forma, a inibição da responsividade dos mastócitos, quando ativados por um alérgeno, representa uma via importante para o desenvolvimento de novos candidatos a fármacos com indicação antialérgica. Neste sentido, este trabalho buscou, num primeiro momento, contribuir com a compreensão dos papéis desempenhados por um glicerofosfolipídeo de membrana, fosfatidilinositol 4,5-bifosfato (PtdIns(4,5)P2), em eventos de sinalização em mastócitos, mediados por IgE. Este trabalho permitiu destacar a importância de PtdIns(4,5)P2 como um regulador chave das respostas de Ca2+ e das alterações de morfologia de mastócitos estimulados por um alérgeno. Foi observado ainda que níveis reduzidos de PtdIns(4,5)P2 determinaram a inibição do processo de endocitose de receptores Fc RI ativados, um evento crucial para a redução da transdução de sinais. Estes resultados não somente trazem um ganho de conhecimento acerca dos detalhes que orquestram os eventos de sinalização em mastócitos estimulados por um alérgeno, como também apontam que a regulação dos níveis de PtdIns(4,5)P2 pode certamente ser apontada como alvo para o desenvolvimento de novas moléculas inibidoras da ativação mastocitária. A segunda etapa deste trabalho teve como objetivo avaliar o potencial inibitório de alguns compostos de origem natural e sintética sobre a degranulação de mastócitos, evento em que mediadores alérgicos, como a histamina, são secretados, em resposta ao estímulo celular. Inicialmente, avaliou-se o efeito inibitório de um conjunto de arilcumarinas sintéticas, estruturalmente relacionadas, sobre a degranulação. Um número significativo de moléculas foram ativas e, dentre elas, algumas substituições junto à estrutura do anel 3-fenilcumarínico, como as hidroxilações das posições 6, 2\'e 5\', puderam ser identificadas como importantes para o potencial bioativo. Finalmente, o trabalho apresentou uma molécula de origem natural, como um potente inibidor da degranulação de mastócitos e da secreção de citocinas. Trata-se da piridovericina, um metabólito secundário, isolado do fungo entomopatogênico Beauveria bassiana. Dessa forma, tanto as cumarinas, como a piridovericina podem ser apontadas como compostos de partida de grande potencial para o desenvolvimento de novos fármacos anti-alérgicos. / Allergic diseases have approached epidemic proportions worldwide. The activation of IgE receptors, Fc RI, from mast cells, is the key event for the initiation and propagation of pathophysiological responses involved in the allergic processes. The interaction between mast cells and allergens triggers a signaling cascade, which results in secretion of pre-formed allergic mediators, through regulated exocytosis, in addition to the synthesis and secretion of lipid mediators and cytokines. In this way, the inhibition of mast cell responsiveness, upon allergen stimulation, represents an important pathway for the development of new antiallergic drug candidates. Thus, the present work tried, firstly, to gain better insight of the roles played by phosphatidylinositol 4,5-biphosphate (PtdIns(4,5)P2) during IgE-mediated mast cell signaling. This work highlighted the importance of PtdIns(4,5)P2 as a key regulator of Ca2+ responses and mast cell morphological alteration, when activated by an allergen. It was observed that reduced levels of PtdIns(4,5)P2 determined the inhibition of activated Fc RI endocytosis, a crucial event for signal transduction termination. Those results not only improve the actual knowledge in mast cell signaling but also point out the regulation of PtsIns(4,5)P2 levels as a target to be pursued during the development of new inhibitors of mast cell activation. The second part of this work aimed to evaluate the capacity of both synthetic and natural compounds to inhibit mast cell degranulation, characterized by the release of granule-contained allergic mediators, such as histamine, upon cell stimulation. Initially, the inhibitory effect of a set of structurally related synthetic arylcoumarins was evaluated. A significant number of molecules were active, and a few substitutions within such molecules could be pointed as important for the biological activity, such as the hydroxylation of carbons 6, 2\' e 5\' of the 3-phenylcoumarin ring. Lastly, this work presents a natural compound as a potent inhibitor of mast cell degranulation and cytokine secretion. The refered compound is pyridovericin, a secondary metabolite isolated from the entomophatogenic fungus Beauveria bassiana. Therefore, both the coumarin derivatives and pyridovericin can be regarded as lead compounds for the development of new anti-allergic drugs.

As doenças alérgicas alcançaram proporções mundialmente epidêmicas. A ativação de receptores para IgE, Fc RI, em mastócitos, é o mecanismo chave para a iniciação e propagação das respostas patofisiológicas dos processos alérgicos. Após a interação destas células com um alérgeno, há a ativação de uma cascata de eventos de sinalização, a qual resulta na secreção de mediadores alérgicos pré-formados, através de um processo regulado de exocitose, além da síntese e secreção de mediadores lipídicos e citocinas. Desta forma, a inibição da responsividade dos mastócitos, quando ativados por um alérgeno, representa uma via importante para o desenvolvimento de novos candidatos a fármacos com indicação antialérgica. Neste sentido, este trabalho buscou, num primeiro momento, contribuir com a compreensão dos papéis desempenhados por um glicerofosfolipídeo de membrana, fosfatidilinositol 4,5-bifosfato (PtdIns(4,5)P2), em eventos de sinalização em mastócitos, mediados por IgE. Este trabalho permitiu destacar a importância de PtdIns(4,5)P2 como um regulador chave das respostas de Ca2+ e das alterações de morfologia de mastócitos estimulados por um alérgeno. Foi observado ainda que níveis reduzidos de PtdIns(4,5)P2 determinaram a inibição do processo de endocitose de receptores Fc RI ativados, um evento crucial para a redução da transdução de sinais. Estes resultados não somente trazem um ganho de conhecimento acerca dos detalhes que orquestram os eventos de sinalização em mastócitos estimulados por um alérgeno, como também apontam que a regulação dos níveis de PtdIns(4,5)P2 pode certamente ser apontada como alvo para o desenvolvimento de novas moléculas inibidoras da ativação mastocitária. A segunda etapa deste trabalho teve como objetivo avaliar o potencial inibitório de alguns compostos de origem natural e sintética sobre a degranulação de mastócitos, evento em que mediadores alérgicos, como a histamina, são secretados, em resposta ao estímulo celular. Inicialmente, avaliou-se o efeito inibitório de um conjunto de arilcumarinas sintéticas, estruturalmente relacionadas, sobre a degranulação. Um número significativo de moléculas foram ativas e, dentre elas, algumas substituições junto à estrutura do anel 3-fenilcumarínico, como as hidroxilações das posições 6, 2\'e 5\', puderam ser identificadas como importantes para o potencial bioativo. Finalmente, o trabalho apresentou uma molécula de origem natural, como um potente inibidor da degranulação de mastócitos e da secreção de citocinas. Trata-se da piridovericina, um metabólito secundário, isolado do fungo entomopatogênico Beauveria bassiana. Dessa forma, tanto as cumarinas, como a piridovericina podem ser apontadas como compostos de partida de grande potencial para o desenvolvimento de novos fármacos anti-alérgicos. / Allergic diseases have approached epidemic proportions worldwide. The activation of IgE receptors, Fc RI, from mast cells, is the key event for the initiation and propagation of pathophysiological responses involved in the allergic processes. The interaction between mast cells and allergens triggers a signaling cascade, which results in secretion of pre-formed allergic mediators, through regulated exocytosis, in addition to the synthesis and secretion of lipid mediators and cytokines. In this way, the inhibition of mast cell responsiveness, upon allergen stimulation, represents an important pathway for the development of new antiallergic drug candidates. Thus, the present work tried, firstly, to gain better insight of the roles played by phosphatidylinositol 4,5-biphosphate (PtdIns(4,5)P2) during IgE-mediated mast cell signaling. This work highlighted the importance of PtdIns(4,5)P2 as a key regulator of Ca2+ responses and mast cell morphological alteration, when activated by an allergen. It was observed that reduced levels of PtdIns(4,5)P2 determined the inhibition of activated Fc RI endocytosis, a crucial event for signal transduction termination. Those results not only improve the actual knowledge in mast cell signaling but also point out the regulation of PtsIns(4,5)P2 levels as a target to be pursued during the development of new inhibitors of mast cell activation. The second part of this work aimed to evaluate the capacity of both synthetic and natural compounds to inhibit mast cell degranulation, characterized by the release of granule-contained allergic mediators, such as histamine, upon cell stimulation. Initially, the inhibitory effect of a set of structurally related synthetic arylcoumarins was evaluated. A significant number of molecules were active, and a few substitutions within such molecules could be pointed as important for the biological activity, such as the hydroxylation of carbons 6, 2\' e 5\' of the 3-phenylcoumarin ring. Lastly, this work presents a natural compound as a potent inhibitor of mast cell degranulation and cytokine secretion. The refered compound is pyridovericin, a secondary metabolite isolated from the entomophatogenic fungus Beauveria bassiana. Therefore, both the coumarin derivatives and pyridovericin can be regarded as lead compounds for the development of new anti-allergic drugs.

The lipid kinase phosphatidylinositol 4-kinase III β (PI4KIIIβ) phosphorylates phosphatidylinositol (PtdIns) to generate PI(4)P in the Golgi. PI4KIIIβ is likely involved in the development of breast cancer as it has been reported genetically amplified in a subset of human breast tumours and is a downstream effector of the eukaryotic elongation factor 1 alpha 2 (eEF1A2), a transforming gene that is amplified and highly expressed in approximately 60% of human breast tumours. The goal of my thesis is to investigate a role for PI4KIIIβ in breast oncogenesis. We show that PI4KIIIβ is highly expressed in approximately 20% of primary human breast tumours. Overexpression of PI4KIIIβ in an invasive breast ductal carcinomas cell line, BT549, increased the production of filopodial actin filament protrusions and enhanced in vitro proliferative capacity. Enhanced PI4KIIIβ expression did not impact the migratory rate of these breast cancer cells. We found that PI4KIIIβ expression activates Akt kinase in the BT549 breast cancer cell line. PI4KIIIβ overexpression led to an increase in the plasma membrane abundance of the PI3K derived PI(3,4,5)P3/PI(3,4)P2 lipids, upstream activators of Akt signalling. PI(4)P and PI(4,5)P2 are precursors to PI(3,4,5)P3 and PI(3,4)P2 generation, however, no changes in the overall cellular abundance or localization of PI(4)P or PI(4,5)P2 were detected in PI4KIIIβ-overexpressing cells. Inhibition of PI4KIIIβ kinase activity, using the drug Pik93, had no effect on PI4KIIIβ-mediated Akt activation. Additionally, ectopic expression of a catalytically inactive PI4KIIIβ also led to increased Akt activity and PI(3,4,5)P3/PI(3,4)P2 plasma membrane abundance. Together, this implies that PI4KIIIβ regulates Akt independently of PI(4)P generation. The PI4KIIIβ interacting protein, Rab11, is likely involved in PI4KIIIβ mediated Akt activation, as RNAi-mediated depletion of Rab11 suppressed the effect of PI4KIIIβ overexpression on Akt activation. Furthermore, PI4KIIIβ overexpression altered cellular Rab11 distribution and led to enhanced recruitment of PI4KIIIβ and Rab11 to recycling endosomes. Therefore, PI4KIIIβ is highly expressed in a subset of breast tumours and upregulated PI4KIIIβ expression enhances filopodia production and cell growth in vitro. Enhanced PI4KIIIβ expression increases PI(3,4,5)P3/PI(3,4)P2 plasma membrane abundance and Akt activation independently of its kinase function, through a mechanism that likely involves Rab11. This work suggests that PI4KIIIβ impacts breast oncogenesis by regulating PI3K/Akt signalling through Rab11 and endosomal trafficking.

No description available.